Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma
Citations Over TimeTop 10% of 2013 papers
Abstract
The STAT3 gene is abnormally active in glioblastoma (GBM) and is a critically important mediator of tumor growth and therapeutic resistance in GBM. Thus, for poorly treated brain cancers such as gliomas, astrocytomas, and glioblastomas, which harbor constitutively activated STAT3, a STAT3-targeting therapeutic will be of significant importance. Herein, we report a most potent, small molecule, nonphosphorylated STAT3 inhibitor, 31 (SH-4-54) that strongly binds to STAT3 protein (K D = 300 nM). Inhibitor 31 potently kills glioblastoma brain cancer stem cells (BTSCs) and effectively suppresses STAT3 phosphorylation and its downstream transcriptional targets at low nM concentrations. Moreover, in vivo, 31 exhibited blood-brain barrier permeability, potently controlled glioma tumor growth, and inhibited pSTAT3 in vivo. This work, for the first time, demonstrates the power of STAT3 inhibitors for the treatment of BTSCs and validates the therapeutic efficacy of a STAT3 inhibitor for GBM clinical application.
Related Papers
- → LncRNA LINC01094 contributes to glioma progression by modulating miR-224-5p/CHSY1 axis(2021)19 cited
- → MiRNA-93 functions as an oncogene in glioma by directly targeting RBL2.(2018)25 cited
- → Melanoma-associated antigen A2 is overexpressed in glioma and associated with poor prognosis in glioma patients(2018)7 cited
- → CPLX2 is a novel tumor suppressor and improves the prognosis in glioma(2024)2 cited
- → CPLX2 is a novel tumor suppressor and improves the prognosis in glioma(2023)